S-(+)-apomorphine | 39478-62-1

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 阿朴菲
• 英文名称: S-(+)-apomorphine
• 英文别名: (+)-Apomorphine；Apomorphin；(6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
• CAS: 39478-62-1
• 化学式: C₁₇H₁₇NO₂
• mdl: MFCD00599418
• 分子量: 267.327
• InChiKey: VMWNQDUVQKEIOC-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  20
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  43.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  可待因 在 甲烷磺酸 、 DL-蛋氨酸 作用下， 反应 24.0h， 生成 S-(+)-apomorphine
  参考文献：
  名称：

  Csutoras, Csaba; Berenyi, Sandor; Makleit, Sandor, Synthetic Communications, 1996, vol. 26, # 12, p. 2251 - 2256

  摘要：

  DOI：

文献信息

• [EN] PHARMACEUTICAL COMPOSITIONS OF (6AS)-6-METHYL-5,6,6A,7-TETRAHYDRO-4H-DIBENZO[DE,G]QUINOLINE-10,11-DIOL<br/>[FR] COMPOSITIONS PHARMACEUTIQUES DE (6AS)-6-MÉTHYL -5,6,6A,7-TÉTRAHYDRO-4 H-DIBENZO[DE,G]QUINOLÉINE-10,11-DIOL
  申请人：ACLIPSE ONE INC

  公开号：WO2021026421A1

  公开（公告）日：2021-02-11

  This invention relates to pharmaceutical compositions for enhancing the solubility of (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol and salt forms thereof.

  这项发明涉及用于增强(6aS)-6-甲基-5,6,6a,7-四氢-4H-二苯并[de,g]喹啉-10,11-二酚及其盐形式溶解度的制药组合物。
• [EN] PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES<br/>[FR] COMPOSITION PHARMACEUTIQUE DESTINÉE À ÊTRE UTILISÉE DANS LE TRAITEMENT DE MALADIES NEUROLOGIQUES
  申请人：ACLIPSE ONE INC

  公开号：WO2021026413A1

  公开（公告）日：2021-02-11

  The present invention relates to pharmaceutical compositions for administration to mammals that include (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient that provides pharmacokinetic profiles useful for the treatment of neurodegenerative diseases.

  本发明涉及用于给哺乳动物的药物组合物，包括（6aS）-6-甲基-5,6,6a,7-四氢-4H-二苯并[de,g]喹啉-10,11-二酚或其药用可接受的盐，以及至少一种提供药代动力学特性的药用可接受的赋形剂，用于治疗神经退行性疾病。
• Convenient Synthesis of (S)-(+)-Apomorphine from (R)−(−)-Apomorphine
  作者：Patrick J. Davis、Selim Seyhan、William Soine、Robert V. Smith

  DOI：10.1002/jps.2600690918

  日期：1980.9

  preparing (S)-(+)-apomorphine from (R)-(-)-apomorphine. Dehydrogenation of the dimethyl ether of (R)-(-)-apomorphine with 10% palladium-on-carbon followed by reduction with sodium cyanoborohydride under acidic conditions resulted in quantitative racemization to give (R,S)-apomorphine dimethyl ether, which then was resolved with (-)-tartaric acid. Ether cleavage of (S)-(+)-apomorphine dimethyl ether (-)-tartrate

  设计了一种从（R）-（-）-阿扑吗啡制备（S）-（+）-阿扑吗啡的方法。（R）-（-）-阿扑吗啡的二甲醚用10％的碳载钯脱氢，然后在酸性条件下用氰基硼氢化钠还原，导致定量消旋生成（R，S）-阿扑吗啡二甲醚用（-）-酒石酸拆分。（S）-（+）-阿扑吗啡二甲醚（-）-酒石酸酯与氢溴酸在乙酸酐中的醚裂解生成（S）-（+）-阿扑吗啡，其分离成盐酸盐形式，过量99％对映体。
• Quaternary Ammonium Salt Prodrugs
  申请人：Almarsson Orn

  公开号：US20110178068A1

  公开（公告）日：2011-07-21

  The invention provides a method of sustained delivery of a tertiary amine-containing parent drug comprising administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile quaternary ammonium salts of tertiary amine-containing parent drugs (or tertiary imine-containing parent drugs) that are derivatized through aldehyde-linked prodrug moieties that reduce the solubility of the prodrug compound at a reference pH as compared to the parent drug. The physical, chemical and solubility properties of these derivatives can be further modulated by the choice of counterion X − . In one embodiment, the present invention provides a prodrug compound of Formula I: where R 1 -R 5 are defined in the written description of the invention. The prodrug compounds of the invention can be used to treat any condition for which the tertiary amine-containing parent drug or tertiary imine-containing parent drug is useful as a treatment.

  本发明提供了一种持续释放三级胺含有的母药的方法，包括向患者施用本发明的前药化合物的有效量，其中在向患者施用时，母药从前药中的释放是持续释放的。适用于本发明方法的前药化合物是由醛基连接的前药基团衍生的，这些前药基团可以减少前药化合物在参考pH下的溶解度与母药相比。这些衍生物的物理、化学和溶解度特性可以通过选择阴离子X-来进一步调节。在一种实施方式中，本发明提供了式I的前药化合物：其中R1-R5在发明的书面描述中被定义。本发明的前药化合物可用于治疗任何需要使用三级胺含有的母药或三级亚胺含有的母药进行治疗的情况。
• AGENT FOR IMPROVING MITOCHONDRIAL DYSFUNCTION, PREVENTATIVE OR THERAPEUTIC AGENT FOR DISEASES OR SYMPTOMS CAUSED BY MITOCHONDRIAL DYSFUNCTION, AND APPLICATIONS THEREFOR
  申请人：Jichi Medical University

  公开号：EP3708161A1

  公开（公告）日：2020-09-16

  An object of the present invention is to provide a means for substantially improving mitochondrial dysfunction. An aspect of the present invention relates to an agent for improving mitochondrial dysfunction, comprising a compound represented by the following formula, a stereoisomer or a salt thereof, or a solvate thereof, as an active ingredient. Another aspect of the present invention relates to a medicament or a pharmaceutical composition comprising the aforementioned compound, a stereoisomer or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, as an active ingredient, for use in preventing or treating a disease or symptom caused by mitochondrial dysfunction.

  本发明的目的是提供一种实质性改善线粒体功能障碍的方法。本发明的一个方面涉及一种改善线粒体功能障碍的制剂，该制剂包含下式所代表的化合物、其立体异构体或盐，或其溶解物作为活性成分。本发明的另一方面涉及一种药物或药物组合物，包含上述化合物、其立体异构体或其药学上可接受的盐，或其药学上可接受的溶液，作为活性成分，用于预防或治疗由线粒体功能障碍引起的疾病或症状。